Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000793729 | SCV000933096 | uncertain significance | Myofibrillar myopathy 4 | 2023-12-13 | criteria provided, single submitter | clinical testing | The LDB3 gene has multiple clinically relevant transcripts. This variant occurs in alternate transcript NM_007078.3, and corresponds to NM_001080116.1:c.*17354A>G in the primary transcript. This sequence change replaces serine, which is neutral and polar, with glycine, which is neutral and non-polar, at codon 545 of the LDB3 protein (p.Ser545Gly). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with LDB3-related conditions. ClinVar contains an entry for this variant (Variation ID: 640656). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Victorian Clinical Genetics Services, |
RCV002470983 | SCV002769436 | uncertain significance | Familial isolated dilated cardiomyopathy | 2021-05-06 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as VUS-3B. Following criteria are met: 0102 - Loss of function is the proposed mechanism of disease in this gene associated with missense variants and is associated with dilated cardiomyopathy, 1C, with or without LVNC (MIM#601493), hypertrophic cardiomyopathy, 24 (MIM#601493), left ventricular noncompaction 3 (MIM#601493) and myofibrillar myopathy, 4 (MIM#609452) (PMID: 19377068). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from serine to glycine. (I) 0251 - This variant is heterozygous. (I) 0302 - Variant is present in gnomAD (v2) <0.001 for a dominant condition (2 heterozygotes, 0 homozygotes). (SP) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0807 - This variant has no previous evidence of pathogenicity. (I) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1206 - This variant has been shown to be paternally inherited. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Fulgent Genetics, |
RCV002493446 | SCV002782383 | uncertain significance | Dilated cardiomyopathy 1C; Myofibrillar myopathy 4 | 2021-08-12 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003480824 | SCV004225285 | uncertain significance | not provided | 2022-10-19 | criteria provided, single submitter | clinical testing | BP4 |
Ambry Genetics | RCV004994009 | SCV005612243 | uncertain significance | Cardiovascular phenotype | 2024-08-04 | criteria provided, single submitter | clinical testing | The c.1633A>G (p.S545G) alteration is located in exon 9 (coding exon 9) of the LDB3 gene. This alteration results from a A to G substitution at nucleotide position 1633, causing the serine (S) at amino acid position 545 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV003480824 | SCV005628372 | uncertain significance | not provided | 2024-07-18 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; Reported using an alternate transcript of the gene |